# DragonFly EU Pivotal Study

Study · id `cardio:ct-nct05927441` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05927441](<https://clinicaltrials.gov/study/NCT05927441>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05927441

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 168 participants.

## Technical summary

Registry record NCT05927441. Non-randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2026-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 168 participants (planned count; ClinicalTrials.gov record NCT05927441, source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)
- Started: 2024-01-01 (actual) (ClinicalTrials.gov record NCT05927441, source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)
- Primary completion: 2026-04-01 (anticipated) (ClinicalTrials.gov record NCT05927441, source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)
- Completion: 2029-05-01 (anticipated) (ClinicalTrials.gov record NCT05927441, source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05927441, source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05927441-2025-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: DragonFly EU Pivotal Study
- Condition: Mitral Valve Insufficiency
- Intervention (Device): DragonFly Transcatheter Mitral Valve Repair System
- Lead sponsor: Hangzhou Valgen Medtech Co., Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Donawa Lifescience Consulting S.r.l.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Hangzhou Valgen Medtech Co., Ltd (`cardio:org-hangzhou-valgen-medtech-co-ltd`)

## Provenance

Content hash: 26e4c48147ff3ea5f2498b89dcfe7889a3dc3d7d0311ee9aad0921396e55c03e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
